Workflow
利厄替尼片(奥壹新)
icon
Search documents
ESMO年会进行中 多家A股公司发布创新药研发进展
Core Insights - The 2025 European Society for Medical Oncology (ESMO) conference will take place in Berlin from October 17 to 21, with several domestic companies planning to disclose data [1] - Zai Lab (688266) will present clinical research data for its new drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) at ESMO [1] - ZG006 is the world's first tri-specific antibody targeting DLL3, showing potential as a best-in-class molecule with significant and durable anti-tumor efficacy in SCLC or NEC patients who have failed existing standard treatments [1] - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody, expected to treat various solid tumors, and is among the first of its kind to enter clinical research globally [1] Company Developments - Zai Lab reported that ZG005 combined with chemotherapy shows good safety and efficacy in patients with advanced neuroendocrine carcinoma, supporting further clinical research [2] - Aosaikang (002755) announced the presentation of data for its new cMET inhibitor ASKC202 combined with Lapatinib for locally advanced or metastatic non-small cell lung cancer, demonstrating good safety and high tumor response rates [2] - Aosaikang's Lapatinib is its third-generation EGFR TKI, and the company believes that the synergy of its two innovative drug projects will enhance its oncology product pipeline [2] Other Company Announcements - Maiwei Biotech (688062) plans to report data on its B7-H3 targeted antibody-drug conjugate 7MW3711 for advanced solid tumors at ESMO [3] - Kelun Pharmaceutical (002422) will present a study comparing the efficacy and safety of Trastuzumab deruxtecan versus Emicizumab in HER2-positive patients who have previously received Trastuzumab and taxane treatments [3] - Academic conferences are crucial catalysts for innovative drug sectors, with major events like ASCO, ESMO, and WCLC being the most significant in the oncology field [3]
奥赛康创新药ASKC202在2025年ESMO年会公布临床研究数据
Bei Jing Shang Bao· 2025-10-19 10:28
奥赛康表示,利厄替尼片(奥壹新)是公司已经上市的第三代EGFR TKI。ASKC202片(cMET抑制 剂)与利厄替尼片联合用药有希望为EGFR-TKI耐药的肺癌患者提供有效解决方案,延长患者生存期。 公司两款创新药项目协同拓展肺癌领域目标人群,有利于进一步完善公司抗肿瘤产品管线,对公司的战 略布局起到积极作用。 北京商报讯(记者 丁宁)10月19日晚间,奥赛康(002755)发布公告称,公司的子公司江苏奥赛康药 业有限公司于10月18日在德国柏林召开的欧洲肿瘤内科学会(ESMO)年会上,以壁报形式首次公布新 型cMET抑制剂ASKC202联合利厄替尼用于经表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)治疗失败 伴MET扩增/过表达的局部晚期或转移性非小细胞肺癌的剂量递增及扩展临床试验研究数据。 ...
深市医药生物公司2025年半年度业绩预告向好 创新驱动与多元布局成双引擎
Zheng Quan Ri Bao Wang· 2025-07-27 12:42
Core Viewpoint - The biopharmaceutical industry in the Shenzhen Stock Exchange is showing a stable and positive performance in the first half of 2025, with 56 companies expected to achieve a net profit between 3.8 billion to 5 billion yuan [1] Group 1: Performance Forecasts - Dabo Medical is expected to achieve a net profit of approximately 230 million to 250 million yuan, representing a year-on-year increase of 66.37% to 80.84% [2] - Aosaikang is projected to realize a net profit of 135 million to 175 million yuan, with a year-on-year growth rate of 78.58% to 131.50% [2] - Jilin Aodong anticipates a net profit of about 1.236 billion to 1.290 billion yuan, reflecting a year-on-year increase of 130% to 140% [3] Group 2: Innovation and R&D - Dabo Medical emphasizes product innovation and international development strategies to maintain healthy business growth [2] - Aosaikang is focusing on the commercialization of its first innovative drug, which marks a significant milestone in its transformation [2] - Aosaikang has over 40 drugs in various stages of development, including more than ten innovative drugs in clinical stages [5] Group 3: Strategic Adjustments - Companies are actively adjusting their operational strategies and optimizing cost structures to enhance resilience and profitability [4] - Dabo Medical plans to strengthen its core business through innovation and international expansion [4] - Jilin Aodong aims to focus on its pharmaceutical core business while leveraging its brand advantages for steady revenue and profit growth [4]
南京不断推动产业强市全面起势︑积厚成势︐加快塑造发展新动能
Nan Jing Ri Bao· 2025-07-16 23:38
Core Viewpoint - Nanjing is accelerating the construction of a modern industrial system, focusing on the "1+4+6" strategy to enhance industrial strength and achieve breakthroughs in key sectors [4][10]. Group 1: Industrial Strategy and Initiatives - The "1+4+6" framework includes the implementation of the three-year action plan for industrial strength, the establishment of four industry promotion offices, and the formation of six specialized industry teams [4][5]. - The city has introduced a series of industrial action plans and support policies targeting 12 industrial directions and 27 sub-fields, clarifying the focus for attracting investment and developing key industries [5][10]. Group 2: Performance and Growth Metrics - In the first half of the year, the core robotics industry in Nanjing achieved revenue of 19.4 billion, reflecting a year-on-year growth of approximately 20% [6]. - The software and information services sector generated 520 billion in revenue, with a growth rate of 16.5%, while the artificial intelligence core industry reached 26 billion, growing by 26% [6][7]. - The biopharmaceutical industry reported revenues of 118.5 billion, marking an 11.5% increase, and the new generation information communication sector achieved 74.2 billion, with a growth of 12.1% [7]. Group 3: Investment and Project Development - Nanjing successfully attracted 105 projects, with a planned investment of approximately 13 billion, including 41 projects with investments exceeding 100 million [7][9]. - Baiyun Electric plans to invest nearly 10 billion in a smart electrical technology park, aiming to create a significant energy industry cluster with projected revenues of 50 billion upon full operation [9]. Group 4: Future Directions and Goals - The city aims to enhance collaboration between government and enterprises, focusing on improving mechanisms, attracting key enterprises, and providing comprehensive project support [10][11]. - The emphasis will be on nurturing a favorable industrial innovation ecosystem, addressing pain points in technology transfer, and fostering long-term capital investment to support industrial breakthroughs [10][11].
一季度全市医药制造业增长百分之十三点七
Nan Jing Ri Bao· 2025-05-06 02:56
Core Insights - The biopharmaceutical industry is a strategic emerging industry crucial for national economy and security, with a significant growth of 13.7% in pharmaceutical manufacturing in Nanjing during Q1 2025, driven by innovation and a vibrant ecosystem of high-tech enterprises [1][8]. Group 1: Innovation and Product Development - Jiangsu Aosai Kang Pharmaceutical Co., Ltd. launched its first class innovative drug, Liratinib tablets, approved for non-small cell lung cancer, marking it as the first innovative drug approved in the province this year [2]. - Nanjing Novozan Biotechnology Co., Ltd. plans to launch six new Alzheimer's disease testing kits, with four being the first of their kind in the country, enhancing early detection capabilities [2][3]. - The new Alzheimer's testing kits are expected to receive regulatory approval by Q3, further simplifying the testing process from cerebrospinal fluid to blood samples [3]. Group 2: Ecosystem and Collaboration - Nanjing has established a deep integration of "industry-university-research-medical" collaboration, positioning itself as a hub for biopharmaceutical innovation, with significant clinical trial and drug approval activity [4][6]. - The city has created a favorable environment for research and development, with over 200 innovation platforms supporting various stages of drug creation [7]. - A strategic cooperation agreement was signed to support biopharmaceutical research and development, with a commitment of 2 billion yuan in diversified capital investment [9][10]. Group 3: Market Growth and Future Plans - The biopharmaceutical industry in Nanjing is projected to generate over 210 billion yuan in revenue in 2024, reflecting a 5% growth, indicating simultaneous scale and quality improvements [8]. - Nanjing aims to enhance its innovation ecosystem by promoting the transformation of cutting-edge research into commercial products, while also attracting leading technology firms [10].